CSPC Pharmaceutical Group Ltd/ HK1093012172 /
20/09/2024 00:00:00 | Chg. +0.30 | Volume | Bid10:08:30 | Ask10:08:30 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
4.99HKD | +6.40% | 254.9 mill. Turnover: 1.21 bill. |
4.98Bid Size: - | 4.99Ask Size: - | 59.41 bill.HKD | - | - |
Assets
|
2019 Unknown in mill. CNY |
2020 HKFRS in mill. CNY |
2021 HKFRS in mill. CNY |
2022 HKFRS in mill. CNY |
2023 HKFRS in mill. CNY |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Property and Equipment | 8,459.2000 | 7,770.4400 | 8,529.3700 | 9,582.0600 | 10,416.5990 | ||||||
Intangible Assets | 1,135.7000 | 508.7400 | 467.8500 | 1,908.1100 | 2,198.5490 | ||||||
Long-Term Investments | 1,077.9000 | 35.4100 | 33.6900 | 62.7400 | 1,527.8680 | ||||||
Fixed Assets | 12,621.4000 | 14,148.8400 | 14,405.0700 | 17,812.6100 | 19,537.2250 | ||||||
Inventories | 2,535.7000 | 1,861.0700 | 2,480.3700 | 2,554.8600 | 3,138.6640 | ||||||
Accounts Receivable | 2,258.8000 | 2,398.8600 | 3,309.1500 | 3,937.9700 | 5,869.2230 | ||||||
Cash and Cash Equivalents | 4,118.2000 | 7,296.0300 | 9,283.6400 | 10,298.0100 | 12,015.2230 | ||||||
Current Assets | 13,697 | 15,921.3700 | 20,336.5000 | 23,957.1600 | 26,744.9450 | ||||||
Total Assets | 26,318.2000 | 30,070.2100 | 34,741.5800 | 41,769.7700 | 46,282.1700 |
Liabilities
|
2019 Unknown in mill. CNY |
2020 HKFRS in mill. CNY |
2021 HKFRS in mill. CNY |
2022 HKFRS in mill. CNY |
2023 HKFRS in mill. CNY |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Accounts Payable | 1,110.9000 | 1,204.5700 | 1,481.3600 | 1,507.9900 | 2,426.1150 | ||||||
Long-term debt | - | - | - | 28.9500 | - | ||||||
Liabilities to Banks | 23 | - | - | - | - | ||||||
Provisions | 563.2000 | 320.4400 | 381.4800 | 611.9900 | 574.8430 | ||||||
Liabilities | 6,800.2000 | 6,969.1300 | 7,913.3500 | 10,127.9000 | 11,264.1580 | ||||||
Share Capital | 10,899.4120 | - | - | - | - | ||||||
Total Equity | 19,518.2000 | 22,332.2900 | 25,986.6700 | 30,197.5300 | 33,203.2080 | ||||||
Minority Interests | 1,056.4000 | 768.7900 | 841.5600 | 1,444.3400 | 1,814.8040 | ||||||
Total liabilities equity | 26,318.2000 | 30,070.2100 | 34,741.5800 | 41,769.7700 | 46,282.1700 |
Income Statement
|
2019 Unknown in mill. CNY |
2020 HKFRS in mill. CNY |
2021 HKFRS in mill. CNY |
2022 HKFRS in mill. CNY |
2023 HKFRS in mill. CNY |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 22,103.2000 | 24,942.2000 | 27,866.8700 | 30,936.9000 | 31,450.1090 | ||||||
Depreciation (total) | - | - | - | - | - | ||||||
Operating Result | 4,600.2000 | - | - | - | - | ||||||
Interest Income | -32.4000 | - | - | - | - | ||||||
Income Before Taxes | 4,626.2000 | - | - | - | - | ||||||
Income Taxes | 892.8000 | 1,162.0100 | 1,158.9700 | 1,350.2100 | 1,316.6790 | ||||||
Minority Interests Profit | -19.2000 | -69.3600 | 82.9400 | 140.6600 | 199.3680 | ||||||
Net Income | 3,714.1000 | 5,159.6600 | 5,605.1900 | 6,091.3900 | 5,873.3250 |
Per Share
Cash Flow
|
2019 Unknown in mill. CNY |
2020 HKFRS in mill. CNY |
2021 HKFRS in mill. CNY |
2022 HKFRS in mill. CNY |
2023 HKFRS in mill. CNY |
||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flow from Operating Activities | 3,783.9000 | 6,739.6100 | 4,636.6300 | 7,627.0600 | 4,178.8150 | ||||||
Cash Flow from Investing Activities | -2,457.2000 | -2,129.5100 | -637.3300 | -6,795.9800 | 607.2670 | ||||||
Cash Flow from Financing | -1,545.5000 | -1,470.9800 | -2,196.6100 | -1,904.0700 | -2,300.9810 | ||||||
Decrease / Increase in Cash | -218.8000 | - | - | - | - | ||||||
Employees | 17,300 | - | - | - | 23,500 |